Ron Activators
The chemicals identified as Ron activators act through intricate modulation of specific signaling pathways, contributing to the indirect activation of Ron. Crizotinib, a tyrosine kinase inhibitors, impacts the HGF/c-Met pathway, influencing c-Met signaling. This modulation indirectly activates Ron, as Ron and c-Met share common downstream signaling cascades, resulting in enhanced Ron activity through altered kinase-dependent events. EHop-016, a Rac1 inhibitor, affects the Rac1 signaling pathway, leading to altered Ron expression and function through modulation of cytoskeletal dynamics. GDC-0941, a PI3K inhibitor, influences the PI3K/AKT pathway, interconnecting with Ron's signaling. This indirect activation enhances Ron activity through altered phosphorylation cascades and downstream signaling events. Ruxolitinib, a JAK1/2 inhibitor, impacts the JAK/STAT pathway, influencing STAT signaling and indirectly activating Ron through transcriptional regulation.
SB203580, a p38 MAPK inhibitor, and Lapatinib, a dual EGFR/HER2 inhibitor, affect the p38 MAPK and EGFR pathways, respectively. They indirectly activate Ron by modulating downstream signaling events shared with Ron, leading to enhanced Ron activity through altered kinase-dependent pathways. AZD4547, an FGFR inhibitor, influences the FGFR pathway, indirectly activating Ron through shared downstream signaling events. XL184, AZD8931, and Gefitinib, targeting multiple tyrosine kinase receptors, modulate MET, EGFR, and HER receptors, respectively. This modulation impacts Ron through common downstream signaling pathways, resulting in enhanced Ron activity through altered kinase-dependent events. Doramapimod, another p38 MAPK inhibitor, influences the p38 MAPK pathway, indirectly activating Ron by modulating downstream signaling events, leading to altered Ron expression and function through kinase-dependent pathways. In summary, these chemicals activate Ron activity through intricate signaling pathway modulation, providing a foundation for further exploration into their regulatory roles in Ron-mediated cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
EHop-016 | 1380432-32-5 | sc-497382 | 5 mg | $78.00 | ||
EHop-016, a Rac1 inhibitor, affects the Rac1 signaling pathway. Its influence on Rac1 can indirectly activate Ron by modulating Rac1-dependent pathways, leading to altered Ron expression and function, enhancing Ron activity through modulation of cytoskeletal dynamics. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $184.00 $195.00 | 2 | |
GDC-0941, a PI3K inhibitor, influences the PI3K/AKT pathway. By modulating PI3K/AKT signaling, GDC-0941 can indirectly activate Ron, as Ron is interconnected with this pathway, leading to enhanced Ron activity through altered phosphorylation cascades and downstream signaling. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib, a JAK1/2 inhibitor, affects the JAK/STAT pathway. Through JAK/STAT pathway modulation, Ruxolitinib can indirectly activate Ron by influencing STAT signaling, leading to altered Ron expression and function, enhancing Ron activity through transcriptional regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, impacts the p38 MAPK pathway. Its influence on p38 MAPK can indirectly activate Ron by modulating downstream signaling events, leading to altered Ron expression and function, enhancing Ron activity through altered kinase-dependent pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib, a dual EGFR/HER2 inhibitor, affects the EGFR signaling pathway. By modulating EGFR signaling, Lapatinib can indirectly activate Ron, as Ron shares common downstream signaling pathways with EGFR, leading to enhanced Ron activity through altered kinase-dependent events. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
AZD4547, a fibroblast growth factor receptor (FGFR) inhibitor, impacts the FGFR pathway. Through FGFR pathway modulation, AZD4547 can indirectly activate Ron by influencing downstream signaling events shared between Ron and FGFR, leading to enhanced Ron activity through altered kinase-dependent pathways. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $92.00 $204.00 | 1 | |
XL184, a tyrosine kinase inhibitor, affects MET and VEGFR2. Through MET inhibition, XL184 can indirectly activate Ron, as Ron shares common downstream signaling pathways with MET, leading to enhanced Ron activity through altered kinase-dependent events and downstream signaling cascades. | ||||||
AZD8931 | 848942-61-0 | sc-364426 sc-364426A | 5 mg 10 mg | $260.00 $490.00 | ||
AZD8931, a dual EGFR/HER2/HER3 inhibitor, impacts EGFR signaling. By modulating EGFR signaling, AZD8931 can indirectly activate Ron, as Ron shares common downstream pathways with EGFR, leading to enhanced Ron activity through altered kinase-dependent events and downstream signaling. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
Doramapimod, a p38 MAPK inhibitor, influences the p38 MAPK pathway. Its impact on p38 MAPK can indirectly activate Ron by modulating downstream signaling events, leading to altered Ron expression and function, enhancing Ron activity through altered kinase-dependent pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib, an EGFR inhibitor, affects the EGFR signaling pathway. By modulating EGFR signaling, Gefitinib can indirectly activate Ron, as Ron shares common downstream signaling pathways with EGFR, leading to enhanced Ron activity through altered kinase-dependent events and downstream signaling. | ||||||